- Tytuł:
- Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial
- Autorzy:
- Źródło:
- In eClinicalMedicine February 2024 68
Czasopismo naukowe